Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 7:21 pm Purchase | 2026-02-09 | 13D | SPYGLASS PHARMA INC SGP | RA CAPITAL MANAGEMENT L.P. | 8,022,639 24.100% | 8,022,639 (New Position) | Filing History |
| 2026-02-17 4:45 pm Purchase | 2025-12-31 | 13G | UNICYCIVE THERAPEUTICS INC UNCY | RA CAPITAL MANAGEMENT L.P. | 2,385,279 9.900% | 425,049 (+21.68%) | Filing History |
| 2026-02-17 4:43 pm Purchase | 2025-12-31 | 13G | SURROZEN INC SRZN | RA CAPITAL MANAGEMENT L.P. | 871,731 9.200% | 4,313 (+0.50%) | Filing History |
| 2026-02-17 4:41 pm Purchase | 2025-12-31 | 13G | RHYTHM PHARMACEUTICALS INC RYTM | RA CAPITAL MANAGEMENT L.P. | 6,666,837 9.900% | 1,105,478 (+19.88%) | Filing History |
| 2026-02-17 4:39 pm Purchase | 2025-12-31 | 13G | PALISADE BIO INC COM P PALI | RA CAPITAL MANAGEMENT L.P. | 15,746,829 9.900% | 5,811,068 (+58.49%) | Filing History |
| 2026-02-17 4:37 pm Sale | 2025-12-31 | 13G | MONOPAR THERAPEUTICS INC MNPR | RA CAPITAL MANAGEMENT L.P. | 667,632 9.900% | -75,229 (-10.13%) | Filing History |
| 2026-02-17 4:35 pm Purchase | 2025-12-31 | 13G | LB PHARMACEUTICALS INC LBRX | RA CAPITAL MANAGEMENT L.P. | 2,208,604 8.700% | 533,604 (+31.86%) | Filing History |
| 2026-02-17 4:33 pm Sale | 2025-12-31 | 13G | LARIMAR THERAPEUTICS INC LRMR | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -6,045,351 (Position Closed) | Filing History |
| 2026-02-17 4:31 pm Purchase | 2025-12-31 | 13G | INVIVYD, INC. IVVD | RA CAPITAL MANAGEMENT L.P. | 28,857,208 9.900% | 7,518,920 (+35.24%) | Filing History |
| 2026-02-17 4:29 pm Purchase | 2025-12-31 | 13G | FULCRUM THERAPEUTICS INC FULC | RA CAPITAL MANAGEMENT L.P. | 6,649,973 9.900% | 596,013 (+9.85%) | Filing History |
| 2026-02-17 4:27 pm Sale | 2025-12-31 | 13G | ELEDON PHARMACEUTICALS INC ELDN | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -3,566,338 (Position Closed) | Filing History |
| 2026-02-17 4:25 pm Sale | 2025-12-31 | 13G | DIANTHUS THERAPEUTICS INC DNTH | RA CAPITAL MANAGEMENT L.P. | 2,611,733 6.000% | -1,255,000 (-32.46%) | Filing History |
| 2026-02-17 4:23 pm Purchase | 2025-12-31 | 13G | CONTINEUM THERAPEUTICS INC CL CTNM | RA CAPITAL MANAGEMENT L.P. | 2,179,711 7.200% | 57,711 (+2.72%) | Filing History |
| 2026-02-17 4:21 pm Purchase | 2025-12-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | RA CAPITAL MANAGEMENT L.P. | 1,939,065 9.900% | 552,898 (+39.89%) | Filing History |
| 2026-02-17 4:19 pm Sale | 2025-12-31 | 13G | ARCELLX INC ACLX | RA CAPITAL MANAGEMENT L.P. | 1,267,156 2.200% | -1,520,171 (-54.54%) | Filing History |
| 2026-02-17 4:17 pm Purchase | 2025-12-31 | 13G | ADICET BIO INC ACET | RA CAPITAL MANAGEMENT L.P. | 960,237 9.900% | 440,954 (+84.92%) | Filing History |
| 2026-02-17 4:15 pm Purchase | 2025-12-31 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | RA CAPITAL MANAGEMENT L.P. | 5,713,852 9.900% | 1,148,985 (+25.17%) | Filing History |
| 2026-02-09 5:01 pm Purchase | 2026-02-02 | 13G | ALX ONCOLOGY HLDGS INC ALXO | RA CAPITAL MANAGEMENT L.P. | 13,117,106 9.900% | 13,117,106 (New Position) | Filing History |
| 2026-02-02 4:30 pm Purchase | 2026-01-26 | 13G | HELIX ACQUISITION CORP. III US HLXC | RA CAPITAL MANAGEMENT L.P. | 1,250,000 7.000% | 1,250,000 (New Position) | Filing History |
| 2026-01-16 4:34 pm Purchase | 2026-01-09 | 13G | CENTURY THERAPEUTICS INC IPSC | RA CAPITAL MANAGEMENT L.P. | 17,944,649 9.900% | 17,944,649 (New Position) | Filing History |